Journal
COLLOIDS AND SURFACES B-BIOINTERFACES
Volume 81, Issue 2, Pages 530-536Publisher
ELSEVIER
DOI: 10.1016/j.colsurfb.2010.07.053
Keywords
LMWSC; Nanoparticle; Paclitaxel; Hydrophobic anticancer drug; Tumor inhibition
Funding
- KITTOLIFE Co.
- Research Foundation of Engineering College, Sunchon National University
Ask authors/readers for more resources
The aim of this study is to prepare delivery vehicles of paclitaxel using low molecular weight water-soluble chitosan (LMWSC) and evaluate them as an anticancer drug delivery system. LMWSC was modified with methoxy polyethylene glycol (LMWSC-MPEG, ChitoPEG), and then it was conjugated with cholesterol (LMWSC-MPEG-Chol). Core-shell type LMWSC-MPEG-Chol nanoparticles (LMWSC-NPs) were prepared by the dialysis method, and the core-shell structure was confirmed by H-1 NMR analysis. To this polymer, paclitaxel was encapsulated and core-shell type nanoparticles were prepared. The release tests indicated that release of paclitaxel from the core-shell type nanoparticles and its transport across the dialysis membrane was slower than dialysis of free paclitaxel. In a cytotoxicity study using CT26 cell, the paclitaxel-encapsulated core-shell type nanoparticles (LMWSC-NPs) showed a toxicity against tumor cells similar to paclitaxel itself. The results of a tumor inhibition test with CT26 implanted upon mouse tumor models in vivo indicated that the application of a dose of 10 mg/kg of LMWSC-NPT showed a superior survival rate, and a slower tumor growth than when paclitaxel alone was administered, although the tumor growth and survival rate were not significantly changed at a dose of 2 mg/kg. The LMWSC-NPT dose above 10 mg/kg showed a superior antitumor activity. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available